

**Biomedical Advanced Research and Development Authority (BARDA)**  
**Rapid Response Partnership Vehicle (RRPV)**



**Request for Project Proposals (RPP)**

**Solicitation Number: RRPV 26-09-AgDx**

**“Agnostic Diagnostics”**

**Request Issue Date: 23 October 2025**

**Due Date: 20 November 2025 by 1pm Eastern**

Biomedical Advanced Research and Development Authority (BARDA)  
Contracts Management & Acquisition (CMA)  
400 7th Street, SW, Washington, DC 20024

[MedicalCountermeasures.gov](https://www.mediccountermeasures.gov)



# 1 Executive Summary

---

## 1.1 Rapid Response Partnership Vehicle Consortium

The Rapid Response Partnership Vehicle (RRPV) Consortium is an enterprise partnership in collaboration with industry and academia to facilitate research and development activities, in cooperation with the Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response, U.S. Department of Health and Human Services (HHS).

The RRPV will help fortify national health security by developing medical countermeasure products prior to and during a pandemic or public health emergency. The RRPV will focus on the acceleration of products and technology development, regulatory approval, commercialization, and sustainment to address pandemic influenza, emerging infectious diseases, and other biological threats.

Advanced Technology International (ATI) has been awarded an Other Transaction Agreement (OTA) by BARDA to serve as the Consortium Management Firm (CMF) for the RRPV.

RRPV is openly recruiting members to join a broad and diverse biomedical consortium that includes representatives from all organizations who work within stated technical focus areas. For more information on the RRPV mission, refer to the RRPV website at [RRPV.org](http://www.rrpv.org). For entities interested in joining the RRPV Consortium and responding to this solicitation, please visit <http://www.rrpv.org/how-to-join>.

## 1.2 Background

Agnostic diagnostics refer to assays or platforms that can be utilized without prior knowledge of—or adaptation to—a specific pathogen or threat agent. Agnostic diagnostics are designed to return positive results when any pathogen that can infect a human is present or negative results when no known human pathogen is present.

Metagenomic Next-Generation Sequencing (mNGS) has demonstrated the ability to agnostically detect and analyze pathogen genomes in research settings. However, the translation of this technology into an FDA-cleared/approved diagnostic has been limited by technical and regulatory challenges. Chief obstacles include integrating multi-vendor components into a single, automated, sample-to-answer system compatible with clinical laboratory workflows, optimizing pathogen-to-host signal-to-noise ratios, and developing validated bioinformatics pipelines and databases acceptable to regulatory authorities. Currently, detection of novel pathogens relies on laboratory-developed tests that lack standardization and reproducibility across sites. No FDA-cleared mNGS-based diagnostic currently exists for either known or emerging pathogen detection.

BARDA seeks to close this gap by establishing a foundational, FDA-cleared mNGS diagnostic capability for known viral and bacterial pathogens that can be rapidly adapted, with only database updates, to novel or emerging threats. Establishing this capability will enhance US public health and biodefense readiness, reduce dependence on single-pathogen assays, and provide a flexible diagnostic infrastructure for rapid response during future public health emergencies.

## 1.3 Purpose

The purpose of this RPP is to support the advanced development, clinical evaluation, and FDA clearance of mNGS-based diagnostic assays for viral and bacterial pathogen detection. BARDA seeks highly flexible, rapidly adaptable systems capable of identifying all known viral and bacterial pathogens within a given specimen (e.g., respiratory sample) and reconfiguring-through database or software updates—to detect

emerging pathogens during public health emergencies. BARDA requires the use of existing mNGS-based sequencing platforms or mNGS platforms that are already in development. Both laboratory and point-of-care mNGS solutions are sought.

## **2 Administrative Overview**

---

### **2.1 RPP Approach**

A multi-stage approach will be employed to streamline the process for preparation, submission, evaluation, and notification. A down selection will occur between Stages 1 and 2. Participation in Stage 1 does not guarantee the opportunity to submit a Full Technical and Cost Proposal in Stage 2, and submission of a Full Technical and Cost Proposal in Stage 2 does not guarantee an award. Each stage of this solicitation process is competitive. Offerors will be invited to participate in the next stage of the process via email from the RRPV Consortium Management Firm (CMF) following the results of the evaluation. All Offerors will receive feedback on eligible submissions.

The solicitation stages are as follows:

#### **Stage 1 - Abstract**

In Stage 1, Offerors will submit an Abstract (not to exceed 5 pages) and a 1-page Quad Chart. Abstracts submitted under this RPP shall follow the mandatory templates provided in Attachment 1. BARDA will evaluate the Stage 1 Abstracts to determine which proposed solutions best meet the evaluation criteria as well as BARDA's current technology priorities and program objectives. Those Offerors will be provided feedback and invited to proceed to Stage 2. Offerors who are not invited to proceed into Stage 2 will be notified.

#### **Stage 2 - (By Invitation Only) Full Technical Proposal & Cost Proposal**

The successful Stage 1 Offeror(s) will receive an invitation letter from the CMF to submit a full technical proposal and cost proposal. Stage 2 is anticipated to require a Technical Proposal, Cost Proposal Narrative, Cost Proposal Format, and Statement of Work. Further instructions will be provided to successful Stage 1 Offerors in the invitation letter.

### **2.2 Order of Precedence**

Each proposal selected for award under this RPP will be executed as a Project Award under the RRPV Base Agreement 75A50123D00005. The same provisions will govern this Base Agreement as the OTA between the U.S. Government (USG) and ATI ("RRPV Base") unless otherwise noted in the Project Award.

### **2.3 Period of Performance and Funding**

#### **2.3.1 Period of Performance**

BARDA estimates the full program Period of Performance to be up to three (3) years from date of award. Specific dates will be negotiated prior to award of the project agreement and may extend beyond 3 years. It is anticipated that the primary place of performance will be the performers' facilities, however this requirement can be negotiated as part of each Performers' submission.

### **2.3.2 Funding**

The total USG funding amount anticipated to be available for Project Awards is approximately \$20M-\$40M, and the USG anticipates making up to 3 awards. Award and funding from the Government is contingent upon the availability of federal funds for this program. The funding estimated for this RPP is approximate and subject to realignment.

### **2.4 Expected Award Date**

Offeror should plan on the period of performance beginning during the second quarter of calendar year 2026. Government reserves the right to change the proposed period of performance start date through negotiations via the RRPV CMF and prior to issuing a Project Award.

### **2.5 Proprietary Information**

The RRPV CMF will oversee submission of abstracts and proposals submitted in response to this RPP. The RRPV CMF shall take the necessary steps to protect all proprietary information and shall not use such proprietary information for purposes other than proposal evaluation and agreement administration. Please mark all Confidential or Proprietary Information as such. An Offeror's submission of a response under this RPP indicates concurrence with the aforementioned CMF responsibilities.

### **2.6 Mandatory Eligibility Criteria**

In order to be eligible for consideration, Offerors must be RRPV members when their Abstract is submitted. Prospective Offerors may join the consortium at [www.rpv.org/how-to-join](http://www.rpv.org/how-to-join).

Abstracts found to not meet minimum eligibility criteria(s) as detailed above may be removed from consideration, no further evaluation will be performed, and feedback will not be provided to these Offerors.

### **2.7 Cost Sharing**

Cost sharing is defined as the resources expended by the Project Awardee on the proposed Statement of Work (SOW). Cost sharing is encouraged, if possible, as it leads to stronger leveraging of Government-Performer collaboration.

### **2.8 Intellectual Property and Data Rights**

Intellectual Property (IP) rights for RRPV Project Awards will be defined in the terms of a Project Awardee's Base Agreement. The RRPV CMF reserves the right to assist in the negotiation of IP, royalties, licensing, future development, etc., between the Government and the Project Awardees during the entire award period.

The Offeror shall comply with the terms and conditions defined in the RRPV Base Agreement regarding Data Rights. **It is anticipated that anything delivered under this proposed effort would be delivered to the Government with unlimited data rights as defined in the RRPV Base Agreement unless otherwise specified in Attachment 1, Abstract, and agreed to by the Government.** All proposed data rights are subject to Government review and approval. Rights in technical data agreed to by the Government will be incorporated into the Project Award.

## 3 Submissions

### 3.1 Question and Answer Period

Key dates related to this RPP are provided below. Please submit questions to Ms. Rebecca Harmon ([rrpv-contracts@ati.org](mailto:rrpv-contracts@ati.org)). Answers will be posted publicly to the RRPV website.

Date	Event	Method
23 Oct 2025	RPP Released	RRPV Website
6 Nov 2025	Proposers Conference	Zoom
10 Nov 2025 12pm Eastern	Questions Due	Email to <a href="mailto:rrpv-contracts@ati.org">rrpv-contracts@ati.org</a>
13 Nov 2025	Answers Released (Approximate)	RRPV Website
20 Nov 2025 1PM Eastern	Abstracts Due	RRPV BDR Portal

### 3.2 General Instructions

The formats provided in this RRPV RPP are mandatory and shall reference this RPP number. ***At the time of the submission, Offerors must certify on the cover page of their Abstract that, if selected for award, they will abide by the terms and conditions of the latest version of the RRPV Base Agreement.*** Offerors may request a current copy of the RRPV Base Agreement terms and conditions by emailing [RRPV-contracts@ati.org](mailto:RRPV-contracts@ati.org). Base Agreements are typically not executed until Offeror is selected for award.

Offerors are encouraged to contact the Point of Contact (POC, see Section 6), identified herein up until the submission date/time to clarify requirements.

Abstracts and Quad Chart shall reference this RPP number. The Abstract and Quad chart is mandatory and shall remain valid for 180 days unless otherwise specified by the Offeror in the submission. Offerors are encouraged to contact the RRPV CMF with any questions so that all aspects are clearly understood by both parties.

All eligible Offerors shall submit Abstracts and Quad charts for evaluation according to the criteria set forth in this RPP. Offerors are advised that only ATI, as the RRPV's CMF, with the approval of the Other Transaction Agreements Officer, is legally authorized to contractually bind or otherwise commit funding for selected Project Awards as result of this RPP.

### 3.3 Abstract and Quad Chart Submission

Abstracts and Quad Charts shall be submitted by the date and time specified on the cover page to the BARDA Digital Resource (BDR) portal website at <https://rrpv.hhs.gov/>. Abstracts received after the date and time specified may not be evaluated.

Offerors will be required to register for a BDR portal account before a response can be submitted. A BDR account can be requested by contacting ATI at [RRPV@ati.org](mailto:RRPV@ati.org). The account request process is simple but may take several days for approval and access. Upon confirmation of a BDR portal account, the Offeror will login using the prescribed two-factor authentication method.

Offerors are strongly encouraged to access the BDR Portal well in advance of the submission due date to verify their ability to log in, confirm account validity, and ensure full access to the submission system. Failure to submit on time for any reason (e.g., due to late registration in BDR portal) will result in the submission not being considered for award. Offerors will be provided an automated confirmation of successful submission.

Do not submit any classified information in the Abstract or Quad Chart submission.

### **3.4 Preparation Cost**

The cost of preparing Abstracts, Quad Charts, and/or Proposals in response to this RPP is not considered a direct charge to any resulting award or any other contract.

### **3.5 Submission Format**

Stage 1 submissions shall consist of a written Abstract of no more than five (5) pages and a Quad Chart of no more than one (1) page, prepared in accordance with the template and formatting instructions in Attachment 1. Submissions exceeding the page limits or not adhering to the prescribed format may be rejected without further review.

## **4 Technical Requirements**

---

### **4.1 Introduction**

The Offeror shall clearly state how it intends to meet and, if possible, exceed the technical requirements. Mere acknowledgement or restatement of the requirements is not acceptable, unless specifically stated otherwise.

### **4.2 Scope**

The proposed product should offer a complete sample-to-answer solution. The proposed product should include sample collection, sample processing (e.g., extraction), library preparation, enrichment/depletion (if needed), sequencing, process controls, and data analysis against a validated database (e.g., a database acceptable to the FDA) of known pathogens. Preferred system characteristics include medium- to high-throughput assays capable of random access/on-demand samples with automated sample preparation, library preparation, sequencing, and analysis with minimal operator intervention. Systems designed to minimize manual reagent handling and waste removal are encouraged. Reagents stable at storage temperatures of 4°C or higher are preferred. Collaboration with the FDA to determine the requirements of a comprehensive sequence database that is acceptable for the proposed product is required. The database should include clinically relevant viral and bacterial pathogen sequences that are quality-controlled, standardized, and validated for detecting viral and bacterial pathogens using mNGS thus ensuring the accuracy and reproducibility of results in a clinical setting.

If the developer funds or cost shares the database build, the database can remain private, though the government encourages public access. If the government funds the database build, the database will be publicly available. The product development strategy should include a plan for the addition of new sequences and validation of proper performance of the test for the detection of a novel pathogen within days of the sequence for the novel pathogen becoming available that is acceptable to FDA (e.g., Predetermined Change Control Plan for Medical Devices).

### 4.3 Performance Objectives

The mNGS device/platform should identify viral and bacterial pathogens utilizing a comprehensive, regulatory-grade database (e.g., detection/identification of all viral and bacterial pathogens in a respiratory specimen) that can quickly be adapted, in collaboration with the FDA, to detect new viral and bacterial pathogens. The mNGS-based assay must utilize existing sequencing reagents and either an existing sequencing platform or a platform in development that is TRL 5 or greater. Information on Technology Readiness Levels (TRLs) for Medical Countermeasure Products (Diagnostics and Medical Devices) can be found here: <https://medicalcountermeasures.gov/trl/trls-for-medical-devices>.

The offeror must provide a regulatory strategy to achieve FDA 510(k) clearance/de novo approval for a diagnostic indication for viral and bacterial pathogens based on feedback from the FDA, with the final milestone of achieving 510(k) clearance/de novo approval. Consideration of FDA guidance for bacterial or viral diagnostics or providing product-specific FDA correspondence regarding the proposed mNGS system will be helpful for framing initial discussions.

Respondents must submit a clear strategy for creating contrived specimens (as agreed upon with the FDA) with varying viral and bacterial loads and for obtaining clinical specimens for validation (a stepwise validation plan is acceptable). A strategy to complete full analytical and clinical validation, and methods for determining a positive result such as percentage of genome, depth of coverage, and quality score should be provided.

The platform should be able to use multiple clinical specimen types and abstract submissions must include feasibility data demonstrating that both viral and bacterial pathogen nucleic acids (DNA and RNA) at clinically-relevant concentrations can be adequately extracted and analyzed from at least one (1) specimen type that is easily obtained (e.g., RNA and DNA from pathogens in nasal swab, nasal pharyngeal swab, saliva, oral fluid, fingerstick or venous whole blood sample). Platforms that yield clear, clinically actionable data reports (e.g., pathogen identification and drug resistance profile), with total time from specimen receipt to result in less than 12 hours are preferred.

### 4.4 Out of Scope Topics

**Abstracts on the following topics will be considered out of scope:**

- R&D activities for Laboratory Developed Test (LDT) or Research Use Only (RUO) mNGS-assay development that do not support a regulatory path for FDA clearance/approval.
- Development of new sequencing platforms. BARDA is primarily interested in products that leverage existing clinical health infrastructure and readily available sequencing platforms that would require minimal capital investment for laboratories to implement.
- Surveillance and environmental testing.
- Development of targeted NGS assays.



Abstracts determined to be out of scope as detailed above may be removed from consideration, no further evaluation will be performed, and feedback will not be provided to these Offerors.

## 5 Selection/Evaluation

---

### 5.1 Compliance Screening

The RRPV CMF will conduct a preliminary screening of submitted Abstracts to ensure compliance with the RPP requirements. As part of the preliminary screening process, submissions that do not meet the requirements of the RPP may be eliminated from the competition or additional information may be requested by the RRPV CMF. The Government reserves the right to request additional information, perform a pre-award audit, or eliminate from further consideration Abstracts that do not meet these requirements.

### 5.2 Evaluation Process

Following the preliminary screening, the Government sponsor will perform source selection using the evaluation factors detailed below. The Government will conduct an evaluation of all qualified Proposals.

Qualified Proposals will be evaluated by a panel of subject matter experts (SMEs) who will make recommendations to a Source Selection Authority.

This process may involve the use of contractors as SME consultants or reviewers. Where appropriate, the USG will employ non-disclosure agreements to protect information contained in the RPP. An Offeror's submission of an Abstract and/or Proposal under this RPP indicates concurrence with the aforementioned use of contractors and SMEs.

#### 5.2.1. Stage 1 and 2:

Following the preliminary screening by the CMF for compliance with the RPP requirements, BARDA will perform an evaluation of all eligible Stage 1 Abstracts and Stage 2 Proposals.

Evaluation of Stage 1 Abstracts and Stage 2 Proposals will be based on an independent, comprehensive review and assessment of the work proposed. The Government will evaluate each Abstract and Proposal against the evaluation factors detailed below and assign one of the following adjectival ratings in order to determine the best value to the Government.

- Outstanding
- Good
- Acceptable
- Marginal
- Unacceptable

Stage 1 Abstract and Stage 2 Proposal evaluation factors are as follows:

**Evaluation Factor 1 - Technical Approach:** This factor evaluates the relevancy, thoroughness, completeness, and feasibility of the proposed approach and the feasibility of proposed schedule.

**Evaluation Factor 2 – Relevant Experience:** This factor evaluates the offeror's demonstrated organizational experience, as well as the technical and management experience of the proposed team to perform the



proposed work. The Government may also consider information in Contractor Performance Assessment Reporting System (CPARS), and the Federal Awardee Performance and Integrity Information System (FAPIS) or similar systems.

**Evaluation Factor 3 – Cost Reasonableness:** Assessment of the cost of the project to determine i) whether the project cost is within the available funding limits, and ii) the ability and/or likelihood of the offeror to successfully execute the proposed project within the financial resources proposed.

### 5.3 Cost/Price Evaluation

Successful Stage 1 Offerors will be invited to submit full proposals. If a proposal is selected for award, the RRPV CMF will evaluate the estimated cost proposed by the Offeror for performing all requirements outlined in this RPP. Evaluation will include analysis of the proposed cost together with all supporting information. The RRPV CMF will request additional information or clarification as necessary. The RRPV CMF will assess the reasonableness and completeness of the cost estimates and then provide a formal assessment to the Government. The Government will review this assessment and make the final determination that the project value is fair and reasonable, subject to final Government negotiations. Proposals will be evaluated using the understanding of cost realism, reasonableness and completeness as outlined below:

**a) Realism.** Proposals will be evaluated to determine if Costs are realistic for the work to be performed, reflect a clear understanding of the requirements, and are consistent with the various elements of the Offeror's schedule proposal.

Estimates are “realistic” when they are neither excessive nor insufficient for the effort to be accomplished. Estimates must also be realistic for each phase of the proposed project when compared to the total proposed cost.

The RRPV CMF will make a determination by directly comparing proposed costs with comparable current and historical data, evaluator experience, available estimates, etc. Proposed estimates will be compared with the corresponding technical proposals for consistency.

**b) Reasonableness.** The Offeror's cost proposal will be evaluated to determine if it is reasonable. For a price to be reasonable, it must represent a price to the Government that a prudent person would pay in the conduct of competitive business. Normally, price reasonableness is established through cost and price analysis.

To be considered reasonable, the Offeror's cost estimate should be developed from applicable historic cost data. The Offeror should show that sound, rational judgment was used in deriving and applying cost methodologies. Appropriate narrative explanation and justification should be provided for critical cost elements. The overall estimate should be presented in a coherent, organized and systematic manner.

Costs provided shall be clearly attributable to activities or materials as described by the Offeror. Costs should be broken down in the Cost Proposal Format. An optional template is located on the Members-Only RRPV website.

**c) Completeness.** The RRPV CMF will evaluate whether the proposal clearly and thoroughly documents the rationale supporting the proposed cost and is compliant with the requirements of the solicitation.

The proposal should clearly and thoroughly document the cost/price information supporting the proposed cost in sufficient detail and depth. The RRPV CMF will evaluate whether the Offeror's cost proposal is complete with respect to the work proposed. The RRPV CMF will consider substantiation of proposed cost (i.e., supporting data and estimating rationale) for all elements.

Rate and pricing information is required to properly perform the cost analysis of the proposal. If the Offeror is unwilling to provide this information in a timely manner, its proposal will be lacking information that is required to properly evaluate the proposal and the proposal may not be selected for award.

#### **5.4 Best Value**

The Government will conduct the source selection based on the evaluation criteria and ratings listed above. The overall award decision will be based upon a Best Value determination by considering and comparing factors in addition to cost or price. Funding recommendations depend on various factors and programmatic relevance. Based on the evaluation of the Technical Approach, Relevant Experience, and Cost/Price, the Government reserves the right to negotiate and request changes to any or all parts of the SOW. Offerors will have the opportunity to concur with the requested changes, propose further changes and revise cost proposals, as necessary.

#### **5.5 Evaluation Results**

Following the evaluation of the Stage 2 proposals, the Source Selection Authority may:

1. Select the proposal (or some portion of the proposal) for award;
2. Place the proposal in the Basket if funding currently is unavailable; or
3. Reject the proposal (will not be considered for award and will not be placed in the Basket)

*The Government does not guarantee a minimum or maximum number of awards resulting from this solicitation.*

#### **5.6 Basket Provision**

The electronic "Basket" is an innovative acquisition tool. Stage 2 Full Technical and Cost Proposals rated as Acceptable through Outstanding, but not immediately selected for award, may be placed in the Basket for 2 years and eligible for award during that time. Proposals rated as below Acceptable will not be placed in the Basket and will not be eligible for future award. If awarding from the Basket, the Government reserves the right to award whichever proposal best meets its needs.

## 6 Points of Contact

---

Questions related to this RPP should be directed to Ms. Rebecca Harmon ([rrpv-contracts@ati.org](mailto:rrpv-contracts@ati.org)).

All technical questions must be submitted by **November 10, 2025**, to allow for Government response. The Government will respond to questions at its discretion. All questions and responses will be posted to the RRPV Solicitation webpage <https://www.rrpv.org/opportunities/>. Questions received after the stated deadline are not guaranteed a response.

**Once an Offeror has submitted a submission under this RPP, the Government and the RRPV CMF will not discuss evaluation/status until the evaluation results have been provided to the Offerors.**

Solicitation Closed

## ATTACHMENT 1 – ABSTRACT TEMPLATE

---

### ***General Instructions***

The Abstract must address the technical requirements described in the RPP in sufficient detail to permit evaluation from a technical perspective in accordance with the evaluation factors set forth in the RPP. Offerors are strongly encouraged to use pictures and graphics to succinctly represent proposed ideas, organization, etc.

The Abstract shall be limited to 5 pages and Quad Chart limited to 1 page; however, the Cover Page and the Data Rights Assertions are not included in the page count. Pages in excess of this limitation may not be considered. Offerors are advised that the number of pages should be commensurate with the degree of complexity of the proposed effort.

The following formatting requirements apply:

- 12-point font (or larger), single-spaced, single-sided, 8.5 by 11 inches
- Smaller type may be used in figures and tables, but must be 8-point font (or larger)
- Margins on all sides (top, bottom, left, and right) should be at least 1-inch
- Submit files in Microsoft Word, Adobe Acrobat (PDF – portable and searchable document format) formats. ZIP files and other application formats are not acceptable. All files must be print-capable and without a password required. Filenames shall contain the appropriate filename extension (.docx.pdf). Filenames should not contain special characters. IOS users must ensure the entire filename and path are free of spaces and special characters. Movie and sound file attachments or other additional files, will not be accepted.

To ensure Abstracts receive proper consideration, **the format shown below is mandatory**. If there are any items which are not applicable to a specific Abstract, include the section topic in the Abstract with a short explanation as to why it is not applicable.

- Cover page (not included in page count)
- Executive Summary
- Technical approach overview
- Teaming/subcontractors
- Facilities and personnel qualification
- Budget estimation
- Period of Performance/Schedule
- Data Rights Assertions (not included in page count)
- Quad Chart (not included in page count, 1-page limit)

**[Name of Offeror]**  
[Address of Offeror]  
[Phone Number and Email Address of Offeror]

Unique Entity Identifier (UEI) #: [UEI #]  
CAGE code: [CAGE code]

**RRPV 26-09-AgDx**

**[Title of Abstract]**

[Offeror] certifies that, if selected for selected for an Award, the Offeror will abide by the terms and conditions of the RRPV Base Agreement.

[A proprietary data disclosure statement if proprietary data is included. Sample: This Abstract includes data that shall not be disclosed outside the RRPV Consortium Management Firm and the Government and shall not be duplicated, used, or disclosed, in whole or in part, for any purpose other than to evaluate this Abstract and negotiate any subsequent award. If, however, an award agreement is a result of, or in connection with, the submission of this data, the RRPV Consortium Management Firm and the Government shall have the right to duplicate, use, or disclose these data to the extent provided in the resulting agreement. This restriction does not limit the RRPV Consortium Management Firm and the Government's right to use the information contained in these data if they are obtained from another source without restriction. The data subject to this restriction is (clearly identify) and contained on pages (insert page numbers).]

## [Title of Abstract]

### 1. Executive Summary

- Provide the background and the Offeror's understanding of the problem.
- Provide a description of the technology/process.
- Emphasize how the proposed technology/process meets the overall objective specified in this RPP.

### 2. Technical Approach Overview

- Demonstrate how your proposed solution currently meets the Technical Requirements described in **Section 4**.
- Include any previous studies or preliminary data [non-clinical and/or clinical] that support the feasibility of the proposed technology solution.

### 3. Teaming/Subcontractors

- Describe any current or potential partnerships or collaborations that may be of use when developing this process/technology.

### 4. Facilities and Personnel Qualification

- Describe the qualifications and expertise of the key personnel and organizations associated with the proposed solution.
- Detail any past performance(s) that demonstrate relevance to the program objective and solution requirements.
- Identify any key facilities, equipment, and other resources relevant for the solution being proposed.

### 5. Budget Estimation

- Provide rough order of magnitude (ROM) and any pertinent assumptions for the proposed work.

### 6. Period of Performance/Schedule

- Identify the proposed Period of Performance (PoP) in months and describe the overall schedule.

### 7. Data Rights Assertions

- It is anticipated that anything delivered under this proposed effort would be delivered to the Government with unlimited data rights. If this is not the intent, then you should discuss any restricted data rights associated with any proposed deliverables. If applicable, complete the below table for any items to be furnished to the Government with restrictions. *An example is provided. This section is not part of the page count.*

Technical Data or Computer Software to	Basis for Assertion	Asserted Rights	Name of Organization Asserting Restrictions	Deliverables Affected
---	------------------------	--------------------	--	--------------------------

be Furnished with Restrictions				

Solicitation Closed





# Quad Chart Template

Your quad chart must contain the following information and be positioned in a landscape view.  
Any quad chart submitted that exceeds the one-page limit will not be read or evaluated.

PROJECT TITLE, RPP#, TECHNICAL/ADMINISTRATIVE POC (NAME, EMAIL, PHONE), COMPANY NAME & ADDRESS

Proposal Information	Supporting Content and Project Planning Information
<p><u>Objective:</u> Clear, concise (two to three sentences) description of the objectives and methodologies of the effort.</p> <p><u>Description of effort:</u> A bullet list (2-3) of the primary scientific challenges being addressed</p>	<p>Picture or Graphic that Illustrates the research or concept (e.g., data figures, molecule illustrations or processes)</p>
<p><u>Benefits of Proposed Technology:</u></p> <p><u>Challenges:</u></p> <p><u>Maturity of Technology:</u></p>	<p><u>Bullet list of the major goals/milestones by:</u></p> <p><u>Project Year</u></p> <p><u>Proposed Funding</u></p> <p>(Rough Order of Magnitude Estimate)</p>